Brief: Lianbio Completes Enrollment In Pivotal Phase 3 Explorer-Cn Trial Of Mavacamten In Chinese Obstructive Hypertrophic Cardiomyopathy Patients
10/08/2022 13:28
Aug 10 (Reuters) - LianBio LIAN.O :
* LIANBIO COMPLETES ENROLLMENT IN PIVOTAL PHASE 3
EXPLORER-CN
TRIAL OF MAVACAMTEN IN CHINESE OBSTRUCTIVE HYPERTROPHIC
CARDIOMYOPATHY PATIENTS
* LIANBIO - TOPLINE DATA EXPECTED MID-2023
Source text for Eikon: ID:nGNXbDHyzy
Further company coverage: LIAN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on LianBio
See all newsChina's Zeekr prices US IPO at top of range to raise $441 million (updated)
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
LianBio completes strategic review, cuts jobs; shares up
Brief: LianBio Announces Completion Of Strategic Review